Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
“I am pleased with our success to date in being an effective collaborator with Evonik, a company with a long, successful and reliable track record of supporting pharmaceutical supply chains,” said
“We are delighted to be collaborating with Cassava and contributing to fight Alzheimer’s together. We are committed to supporting Cassava in their goals to maintain the quality of life for millions of patients around the world and to further advance potential treatment options,” says Dr Thomas Riermeier, head of Evonik’s Health Care business line. Evonik is one of the world’s largest contract development and manufacturing organizations (CDMO) for active pharmaceutical ingredients and advanced intermediates.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years,
For More Information Contact:
Source: Cassava Sciences, Inc.